ANVS - Annovis falls 16% on Phase 3 data delay for Parkinson's drug
2024-01-24 11:30:45 ET
More on Annovis Bio
- Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO
- Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
- Annovis Bio gains after enrollment update on trial for Alzheimer’s drug
- Annovis Bio reports Q3 results
- Seeking Alpha’s Quant Rating on Annovis Bio